
Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

